B-Cell Lymphoblastic Leukemia (B-ALL) monitoring, minimal residual disease (MRD) detection, bone marrow

Alphabetical Test listing

B-Cell Lymphoblastic Leukemia (B-ALL) monitoring, minimal residual disease (MRD) detection, bone marrow-994

  
B-Cell Lymphoblastic Leukemia (B-ALL) monitoring, minimal residual disease (MRD) detection, bone marrow
  
994
  
LAB994
  
MSO
  
Acute minimal residual disease
ALL-MRD
B-ALL MRD
B-cell ALL MRD
  

Aids in monitoring a previously confirmed diagnosis of B-cell lymphoblastic leukemia

  
Bone marrow
  

Yellow ACD (A or B)

 

  
3.0 mL
  
1.0 mL
  
  • Submission of bilateral specimens is not required
  • Label specimen appropriately (bone marrow)
  

Include 5 to 10 unstained bone marrow aspirate smears, if possible.

  

Yellow ACD (A or B)

  

Dk green Sodium heparin (Na hep), no gel

Lavender (EDTA), 4mL

  

Ambient - 72 hours

Specimen must be received at MCL within 72 hours

  
Mayo Clinic Laboratories (BALLM): R-NX
  
Mo - Sa
  
2 - 4 days
  

Immunophenotyping

  

This test will be processed as a laboratory consultation. An interpretation of the immunophenotypic findings and correlation with the morphologic features will be provided by a hematopathologist for every case.

  

This test is only appropriate for patients who have a previous confirmed diagnosis of B-cell lymphoblastic leukemia.

Treatment with antibodies to CD19 may interfere with the ability to detect minimal residual disease (MRD).

  
88184 - Flow cytometry
first cell surface, cytoplasmic or nuclear marker
88185 x 9 - Flow cytometry
additional cell surface, cytoplasmic or nuclear marker (each)
88188 - Flow Cytometry Interpretation, 9 to 15 Markers (if appropriate)
  
07/02/2019
  
06/11/2020
  
06/12/2020